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MOLECULAR ANALYSIS OF CYSTIC FIBROSIS PATIENTS IN HUNGARY 
– AN UPDATE TO THE MUTATIONAL SPECTRUM
MOLEKULARNA ANALIZA OBOLELIH OD CISTI^NE FIBROZE U MA\ARSKOJ 
– DOPUNE SPEKTRU MUTACIJA
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Summary
Background: In this study the authors present an update to
the CFTR mutation profile in Hungary, utilizing data from
a selected cohort of 45 cystic fibrosis (CF) patients from dif-
ferent regions of the country.
Methods: Depending on the preceding analysis, four differ-
ent mutation detection methods were used. A commercial
assay targeting the most common CF-causing mutations
was performed as the first test followed by an allele spe cific
PCR for CFTRdele2,3(21kb), Sanger sequencing and
MLPA analysis of the coding region of the CFTR gene.
Results: In our recent study 27 different mutations were
detected, including 2 novel ones (c.1037_1038insA and
c.1394C>T). Besides F508del (c.1521_1523delCTT), the
following mutations were found at a frequency of ≥ 4.0%:
W1282X (c.3846G>A), N1303K (c.3909C>G),
CFTRdele2,3(21kb) (c.54-5940_273+10250del21kb)
and 2184insA (c.2052_2053insA). In addition, four muta-
tions (G542X, Y1092X, 621+1G>T, and 2143delT) were
found in more than one allele.
Conclusions: The updated database of Hungarian muta-
tions not only enables to increase the efficiency of the exist-
ing diagnostic approach, but also provides a further refined
basis for the introduction of the molecular newborn screen-
ing (NBS) program in Hungary. 
Keywords: cystic fibrosis, mutational spectrum, newborn
screening
Kratak sadr`aj
Uvod: U ovoj studiji autori predstavljaju nove podatke do -
bijene izu~avanjem profila mutacije CFTR u Ma|arskoj uz
pomo} podataka izabrane grupe od 45 pacijenata sa
cisti~nom fibrozom (CF) iz razli~itih krajeva zemlje. 
Metode: U zavisnosti od prethodne analize, kori{}ene su
~etiri razli~ite metode za detekciju mutacija. Prvo je ra|en
komercijalni test koji ciljano traga za naj~e{}im mutaci -
jama koje izazivaju CF, posle ~ega su primenjeni PCR za
CFTRdele2,3(21 kb), Sanger sekvenciranje i MLPA analiza
kodiraju}eg regiona gena CFTR. 
Rezultati: U na{oj nedavnoj studiji otkriveno je 27 razli -
~itih mutacija, uklju~uju}i dve dotad nepoznate
(c.1037_1038insA i c.1394C>T). Pored F508del (c.1521
_ 1523delCTT), prona|ene su slede}e mutacije sa u~esta-
lo{}u ≥ 4,0%: W1282X (c.3846G>A), N1303K (c.3909C
>G), CFTRdele2,3(21kb) (c.54-5940_273+10250
del21kb) i 2184insA (c.2052_2053insA). Pored toga,
~etiri mutacije (G542X, Y1092X, 621+1G>T i 2143
delT) na|ene su u vi{e od jednog alela. 
Zaklju~ak: Baza podataka o ma|arskim mutacijama dopu -
njena poslednjim informacijama ne samo da omogu}ava
pove}avanje efikasnosti postoje}eg dijagnosti~kog pristupa,
ve} tako|e pru`a dodatno usavr{en osnov za uvo|enje pro-
grama molekularnog skrininga novoro|en~adi (NBS) u
Ma|arskoj. 
Klju~ne re~i: cisti~na fibroza, spektar mutacija, skrining
novoro|en~adi
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Introduction
Cystic fibrosis (CF) is the most common severe
inherited monogenic disease in Caucasians, with an
incidence of 1: 2500. Besides the F508del mutation,
which accounts for the majority of CF alleles, almost
2000 different rare mutations have been described in
the CFTR gene. Although no more than 20 of them
occur at a frequency higher than 0.1% worldwide (1),
the geographical heterogeneity of CF causing alleles
demands the use of population specific mutation
detection panels in order to reach reasonably high
mutation detection rates. 
Here, we present the mutational spectrum of CF
patients in a Hungarian cohort which supplements
the results of our previous study from Eastern
Hungary (2). 
Materials and Methods
Altogether 45 CF patients (22 males and 23
females, 10.1±8.1 years) were involved in this study.
Sample collection and analysis were performed
between 2010 and 2014. We selected patients with a
clinical picture of classical CF, where both disease-
causing mutations were identified. All patient samples
were sent by Hungarian care centers (mainly from the
regions of Budapest, Szeged and Debrecen). DNA
was isolated from peripheral blood leukocytes with
the QIAgen Blood Mini Kit (Qiagen, Hilden,
Germany). 
The first line molecular test – if it had not been
carried out by another laboratory before – was a com-
mercially available multiplex allele specific PCR assay,
which is able to detect 29 mutations and differenti-
ates between hetero- or homozygous forms of
F508del (ElucigeneTM CF29 v.2 kit, Tepnel Diag -
nostics Ltd, Abingdon, UK). Any mutation found
other than F508del was further examined by se -
quence analysis of the corresponding region in order
to determine if one or both alleles were affected. The
first tier assay was complemented by an allele specif-
ic PCR to detect the common »Slavic« deletion,
CFTRdele2,3(21kb) (3). As a second tier mutation
analysis Sanger sequencing of the entire coding
region was employed as described before (2) to find
small-scale mutations elusive of the commercial
assay. According to our previous experience (2), we
started  sequencing of exons 4, 6, 11, 14, 15 and 20,
containing prevalent Hungarian mutations such as
2184insA (c.2052_2053insA), L101X (c.302T>G)
and Y1092X (c.3276C>A); if no alteration was
detected, the remaining exons were also tested. As a
third tier step, MLPA analysis was used to detect
large-scale rearrangements (SALSA MLPA KIT P091-
B1 CFTR, MRC-Holland, Amsterdam, the Nether -
lands). If the sending institution had already per-
formed first-line testing, we carried out only the
second and/or third level of molecular analysis. 
One gross rearrangement in the CFTR gene
(CFTRdele2, c.54-5811_164+2186del273+6780
_273+6961inv) which was detected by MLPA analysis
was confirmed by allele specific PCR and bidirecti onal
sequencing of the junction regions, as described in
the literature (7–9).
The numbering of CFTR exons was done
accor ding to the current recommendations (Ensembl
ENSG00000001626). In the mutation nomenclature
both the legacy names and cDNA based HGVS
names were used as proposed (4). 
Results
Table I shows the distribution of detected mu -
tations in our recent study compared to Czech (5),
Polish (6) and previous Hungarian (2) papers.
Altogether 27 different mutations were found.
F508del was detected in 53.3%, four mutations
(W1282X, N1303K, CFTRdele2,3(21 kb), and
2184insA) were detected in 4.4% of alleles, while
another four mutations (G542X, Y1092X, 621+
1G>T, and 2143delT) were found in more than one
allele. 
As shown in Table II, the commercially available
assay was able to detect 75.9% of the mutations in
our combined mutational database. The allele specif-
ic PCR for CFTRdele2,3(21kb) revealed 4.7% of dis-
ease-causing alleles. By the sequencing of exon 14
2184insA and two other rare mutations (c.2012delT
and c.2002C>T) were found with a frequency of
4.7%, 1.2% and 0.6%, respectively. The remaining
mutations were scattered throughout the entire cod-
ing region of the CFTR gene. MLPA analysis revealed
one deletion affecting exon 2 in one patient in a
hetero zygous form. Allele specific PCR and sequenc-
ing analysis showed that the single exon deletion
detected by MLPA was the same as previously
described by others (10, 11).
Discussion
We updated our existing CF database by merg-
ing recently acquired nationwide results with our pre-
vious data from Eastern Hungary (2). Allele frequen-
cies and proportion of detected mutations at different
levels are listed in Table II. Data of our combined
database are discussed below.
Altogether, 31 different mutations were identi-
fied in our previous and recent studies, two of which
were novel (according to the Clinical and Functional
Translation of CFTR database, cftr2.org and the
Human Gene Mutation Database (HGMD)). These
newly described sequence alterations are most likely
pathogenic. One of them changes the reading frame,
generating a premature stop codon 17 amino acids
downstream (c.1037_1038insA, p.Leu346Hisfs*17).
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c.1521_1523delCTT F508del 70.0% 67.4% 54.5% 53.3%
c.3846G>A W1282X 0.0% 0.6% 0.6% 4.4%
c.3909C>G N1303K 5.0% 2.4% 1.2% 4.4%
c.54-5940_273+10250del21kb CFTRdele2,3(21kb) 5.0% 5.8% 4.5% 4.4%
c.2052_2053insA 2184insA 5.0% 0.4% 1.0% 4.4%
c.1624G>T G542X 3.8% 2.0% 1.7% 2.2%
c.489+1G>T 621+1G>T 0.0% 0.4% 0.3% 2.2%
c.3276C>A Y1092X 1.3% 0.0% 0.1% 2.2%
c.302T>G L101X 2.5% 0.0% 0.1% 1.1%
c.1397C>G S466X 1.3% 0.0% 0.1% 1.1%
c.2012delT 2143delT 0.0% 0.9% 1.8% 2.2%
c.53+1G>T 185+1G>T 0.0% 0.2% 0.0% 1.1%
c.1394C>T p.Thr465Ile 0.0% 0.0% 0.0% 1.1%
c.1037_1038insA p.Leu346Hisfs*17 0.0% 0.0% 0.0% 1.1%
c.2051_2052delAAinsG 2183AA>G 0.0% 0.1% 0.7% 1.1%
c.2657+5G>A 2789+5G>A 0.0% 0.5% 0.0% 1.1%
c.3717+12191C>T 3849+10kbC>T 0.0% 1.7% 3.9% 1.1%
c.215C>A A72D 0.0% 0.0% 0.0% 1.1%
c.3454G>C D1152H 0.0% 0.0% 0.1% 1.1%
c.3731G>A G1244E 0.0% 0.0% 0.0% 1.1%
c.1727G>C G576A 0.0% 0.0% 0.3% 1.1%
c.3302T>A M1101K 0.0% 0.0% 0.0% 1.1%
c.2591_2592delTT 2723delTT 0.0% 0.0% 0.0% 1.1%
c.3822G>A W1274X 0.0% 0.0% 0.0% 1.1%
c.2002C>T R668C 0.0% 0.0% 0.2% 1.1%
c.325_327delTATinsG p.Tyr109Glyfs*4 0.0% 0.0% 0.0% 1.1%
c.54-5811_164+2186del273+6780_273+6961inv CFTRdele2 0.0% 0.2% 0.0% 1.1%
Authenticated | balogh@med.unideb.hu author's copy
Download Date | 8/10/14 2:06 AM
J Med Biochem 2015; 34 4













e11 c.1521_1523delCTT F508del 104 61.2% various CF mutations
Elucigene 
CF29v.2    
75.9%
e23 c.3846G>A W1282X 4 2.4% F508del, 2184insA, W1282
e24 c.3909C>G N1303K 8 4.7% various CF mutations
e12 c.1624G>T G542X 5 2.9% various CF mutations
i11 c.1585-1G>A 1717-1G>A 1 0.6% F508del
e8 c.1040G>C R347P 1 0.6% G542X
e14 c.2051_2052delAAinsG 2183AA>G 1 0.6% D1152H
i16 c.2657+5G>A 2789+5G>A 1 0.6% 621+1G>T
i4 c.489+1G>T 621+1G>T 2 1.2% F508del, 2789+5G>A
e21 c.3454G>C D1152H 1 0.6% 2183AA>G
i22 c.3717+12191C>T 3849+10kbC>T 1 0.6% F508del
i1-i3 c.54-5940_273+ 10250del21kb CFTRdele2,3(21kb) 8 4.7% F508del, N1303K, Y109G "Slavic PCR" 4.7%
e14 c.2052_2053insA 2184insA 8 4.7% F508del, G542X, W1282
Sequencing 
of e14    
6.5%
e14 c.2012delT 2143delT 2 1.2% F508del
e14 c.2002C>T R668C 1 0.6% G576A
e20 c.3276C>A Y1092X 3 1.8% F508del
Sequencing 
of the entire 
coding region
11.8%
e4 c.302T>G L101X 3 1.8% F508del, 2723delTT
e11 c.1397C>G S466X 2 1.2% F508del
i1 c.53+1G>T 185+1G>T 1 0.6% N1303K
e11 c.1394C>T p.Thr465Ile 1 0.6% F508del
e8 c.1037_1038insA p.Leu346Hisfs*17 1 0.6% F508del
e3 c.215C>A A72D 1 0.6% N1303K
e15 c.2491G>T E831X 1 0.6% N1303K
e6 c.658C>T Q220X 1 0.6% F508del
e23 c.3731G>A G1244E 1 0.6% F508del
e13 c.1727G>C G576A 1 0.6% R668C
e20 c.3302T>A M1101K 1 0.6% F508del
e15 c.2591_2592delTT 2723delTT 1 0.6% L101X
e23 c.3822G>A W1274X 1 0.6% F508del
e4 c.325_327delTATinsG p.Tyr109Glyfs*4 1 0.6% CFTRdele2,3(21kb)
i1-i2 c.54-5811_164+2186del273+6780_273+6961inv CFTRdele2 1 0.6% F508del MLPA 0.6%
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Pathogenicity of the detected novel missense muta-
tion c.1394C>T, p.Thr465Ile is supported by the fol-
lowing: 1) the affected residue is located at a phylo-
genetically highly conserved position according to the
orthologs of Bos taurus, Equus caballus, Felis catus,
Mus musculus etc.; 2) another pathogenic mutation
(T465N) affecting the same amino acid residue has
already been described (12); 3) SIFT analysis predicts
a damaging effect on the protein function. 
Eleven mutations reached a frequency higher
than 1%. In accordance with the literature (5, 6), the
decreasing »North-to-South« gradient (13) stands for
the distribution of F508del (104/170 CF alleles)
compared to the Czech Republic, but not to Poland.
F508del was followed by the Mediterranean mutation
N1303K, the »Slavic« mutation CFTRdele2,3(21kb)
and the »Galican« mutation 2184insA, each respon-
sible for 4.7% of all CF alleles, which meets our pre-
vious observations. G542X was detected in 2.9%, the
Israeli mutation W1282X in 2.4%. Other relatively
frequent mutations were Y1092X, L101X found in
1.8% and 621+1G>T, S466X, 2143delT found in
1.2% of the patients. One gross rearrangement
(0.6%) in the CFTR gene (CFTRdele2, c.54-
5811_164+2186del273+6780_273+6961inv)
was detected by MLPA analysis and confirmed by
allele specific PCR and bidirectional sequencing of
the junction regions, as described in the literature (7).
The mutation is characterized by a deletion of
8108bp (part of intron 1, the whole exon 2 and part
of intron 2) with an inverted insertion of 182 bp from
intron 3 (11). 
As demonstrated in Figure 1, geographical ten-
dencies can be recognized in the distribution of both
CFTRdele2,3(21kb) and 2184insA mutations. All but
one CFTRdele2,3(21kb) and 2184insA positive sam-
ples originate from the northern regions of the coun-
try and 2184insA even seems to be restricted to the
northeastern territories of Hungary, which is not
suprising if we consider the high frequency of this
mutation in Western Ukraine (14). 
According to the mapped mutation frequencies
in patients originating from different regions of
Hungary using the commercially available assay
75.9% of the mutations can be identified. The allele
specific PCR for the detection of the common »Slavic«
deletion, CFTRdele2,3(21kb) adds 4.7%, while the
sequencing of exon 14 adds 6.5% to the proportion
of detected mutations. MLPA analysis revealed one
rearrangement (0.6%), while direct sequencing of the
entire coding region of CFTR gene identified 20 CF
alleles (11.8%). 
However, it should be noted that the detection
of CFTRdele2,3(21kb) would have been possible by
MLPA as well.
In conclusion, beside determining mutation dis-
tribution in Hungarian CF patients, our study provides
a good starting point to the genetic testing following
Figure 1 Geographical distribution of CFTRdele2,3(21kb) and 2184insA mutations in Hungary.
Legend: o – CFTRdele2,3(21kb), x – 2184insA, ● – other mutations.
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newborn screening. The commercial allele specific
mutation detection method detects 75.9% of CFTR
mutations. Complementing it with the detection of
other two frequent population-specific alterations (i.e.
CFTRdele2,3(21kb) and 2184insA) ∼85% of muta-
tions can be detected to achieve the required sensitiv-
ity (85–90%) in newborn screening (15 and Milan
Macek, personal communication). 
With the growing popularity of the clinical use of
next generation sequencing (NGS) methods, one
possible solution of the combined (i.e. all tiers) DNA
analysis step of NBS programs would be the use of
those tests.
However, based on our results, it also has to be
emphasized that using NGS methods with a high
error rate in homopolymer regions (e.g. pyrosequenc-
ing or ion semiconductor sequencing) in genetic test-
ing will fail to detect ∼5% of CF alleles (2184insA
mutation). The frequent »Slavic« mutation (∼5%)
would be missed as well unless applying a very high
coverage not usual in germline mutation detection or
using commercially available kits including this muta-
tion, but both of these solutions raise unnecessary
financial burdens.
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